Emapalumab, an anti-IFN-gamma antibody, has been approved for use in primary HLH; high circulating levels of this cytokine in Still’s-MAS provide a target for therapeutic blockade [25]. This evidence concerns the gene IFNG and hemophagocytic syndrome.